Efficacy of Roflumilast Foam, 0.3%, in Patients With Seborrheic Dermatitis: A Double-blind, Vehicle-Controlled Phase 2a Randomized Clinical Trial.
Matthew J Zirwas,Zoe D Draelos,Janet DuBois,Leon H Kircik,Angela Y Moore,Linda Stein Gold,Javier Alonso-Llamazares,Michael Bukhalo,Suzanne Bruce,Kimmie Eads,Lawrence J Green,Scott T Guenthner,Laura K Ferris,Seth B Forman,Steven E Kempers,Edward Lain,Charles W Lynde,David M Pariser,Darryl P Toth,Paul S Yamauchi,Robert C Higham,David Krupa,Patrick Burnett,David R Berk JAMA dermatology（2023）
摘要
ClinicalTrials.gov Identifier: NCT04091646.
更多查看译文
AI 理解论文
溯源树
样例
